# S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

> **NCT07722312** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Servier** · enrollment: 80 (estimated)

## Conditions studied

- Relapsed or Refractory Acute Leukemia
- Relapsed or Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** S243249 600mg
- **DRUG:** S243249 400mg
- **DRUG:** S243249 450mg
- **DRUG:** S243249 300mg

## Key facts

- **NCT ID:** NCT07722312
- **Lead sponsor:** Servier
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-20
- **Primary completion:** 2029-08-11
- **Final completion:** 2030-08-25
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722312, "S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*